🚀Deeptech Edge: I’m Betting on This AI Biotech Trend — You Might Want to Too
Your Weekly Shortcut to Deeptech Investing — Trends, Startup Intel & Investor Playbooks for VCs & Angels in 5 Minutes or Less
Your 3-minute shortcut to tomorrow’s $1B bets—every Tuesday.
Hey investors, big news—AI’s shaking up biotech by inventing antibodies faster than humans, and I’m here to share the details. This week’s got the scoop on what’s hot, a startup to watch, a trick to spot winners, an inbox Q&A, and my take on why this is huge.
Plus, heads-up: my VIPs get the full intel scoop this Thursday—secret startup picks, insider tips, and more you won’t see here.
Let’s jump in. 👇
1️⃣
🧬 The Algorithm Biotech Gold Rush: What I’m Watching (That Most VCs Aren’t)
Picture this: AI isn’t just helping scientists tweak medicines anymore—it’s inventing brand-new drugs all on its own! Startups are using super-smart computer programs to whip up antibodies—those tiny proteins that fight off sickness—and it’s turning biotech into a wild treasure hunt. MIT Tech Review (March 2025) says companies like Generate:Biomedicines…
2️⃣
💸 Why I’ve Got My Eye on Inceptive Therapeutics — Biotech’s Next Big Money-Maker?
Let’s zoom in on Inceptive Therapeutics, a startup that’s got my radar buzzing—and it could be your ticket to a big win. This Palo Alto-based startup, kicked off in late 2023, has already got $100 million from heavyweights like Google Ventures, SoftBank, and Nvidia-backed funds (PitchBook, Q1 2025). Their game? Mixing AI with RNA engineering to whip up …
3️⃣
Investor Playbook: Find the Fast Movers
Want a quick trick to spot startups that’ll grow your money fast? Look for ones that skip a lot of lab time! Old-school drug-making drags on for years with messy labs and human tests—it’s slow and burns cash like crazy. But these new AI startups? They use computer tricks to jump ahead, hitting the market sooner with bigger profits. Ask them: “How much c…
VC Mailbox: “Is AI-First Biotech Real or Just Hype?”
You’ve been hitting my inbox: “Is this AI biotech stuff legit, or all talk?” Here’s the deal—it’s real and worth your money, but don’t just chase hype. The best ones have strong patents to keep their ideas safe and lab proof showing the AI works—like Inceptive’s early RNA tests. Big-name teams are cool, but without patents or results, it’s risky. Look for the combo: AI smarts plus real wins. Oh, and watch out—new drug rules can slow things down a bit.
Personal Note: This Feels Like a Game-Changer
This AI biotech boom takes me back to when computer design software changed architecture—suddenly, buildings went from sketches to digital magic, and early adopters cashed in big. Now it’s biotech’s turn. AI inventing drugs isn’t just faster—it’s rewriting the rules. I’m betting we’ll see billion-dollar companies pop out of this by 2030—say, a $1 million bet today could turn into $5 million in five years. Jump in early, and you’ll be grinning all the way to the bank.
Want More?
👉 Upgrade to Deeptech Signals Premium.
Thursday’s drop is your VIP edge—don’t miss it!
Stay sharp,
Eden Djanashvili
Author Invest Deeptech